Get started

Windtree Therapeutics, Inc

No trades
See on Supercharts
Overview
News Ideas Financials Technicals Forecast

WINT chart

Key stats

Market capitalization
6.435MUSD
Dividends yield (FY)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−53.51USD

About Windtree Therapeutics, Inc

Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Craig E. Fraser
Website
windtreetx.com
Headquarters
Warrington
Employees
20
Founded
1992
ISIN
US97382D4025

Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical and medical device company engaged in the development of novel therapeutics intended to address significant unmet medical needs in important acute care markets. It focuses on the treatment of acute cardiovascular and acute pulmonary diseases. The company was founded by Evan Myrianthopoulos and James S. Kuo on November 6, 1992 and is headquartered in Warrington, PA.

Ideas

WINT - nov 26 : WINT - nov 26 : Wind-tree Is Studying Istaroxime in Early Cardiogenic Shock Patients WARRINGTON, Pa., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmon
WINT - Ready to Double 😵-Windtree Therapeutics Inc (NASDAQ:WINT) shares are trading higher by 32% at $2.63 in Friday's premarket session after Oppenheimer initiated coverage on the stock with an Outperform rating and an $8 price target. -Windtree Therapeutics is a development-stage biotechnology company focused on develop
Long
13
Windtree Therapeutics Inc 🧙Windtree Therapeutics Inc is a development-stage biotechnology company focused on developing KL4 surfactant therapies for respiratory diseases. Its technology platform includes a synthetic, peptide-containing surfactant and novel drug delivery technologies that deliver aerosolized KL4 surfactant wit
Long
1

See all ideas 

News Flow

Keep readingKeep reading

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating

An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Be warned
This info isn't a recommendation for what you should personally do, so please don't take the data as investment advice. As with any trade, always look first, then leap. Read more in the Terms of Use.

Financials

Past performance
Revenue to profit conversion
Total revenue
Gross profit
EBITDA
EBIT
Net income
‪0%‬
‪0%‬
‪0%‬
‪0%‬
‪0%‬
Debt level and coverage
Earnings
Next:—
‪0‬

Trading & brokers

TradeStation
TradeStation
Featured
Stocks, Crypto, Futures
4.44Fabulous
Learn more
OANDA
OANDA
Forex
4.52Great
Learn more
FOREX.com
FOREX.com
Forex
4.38Fabulous
Learn more
Interactive Brokers
Interactive Brokers
Stocks, Futures, Bonds
4.35Fabulous
Learn more

See all brokers 

Gain new superpowers

Take your analysis to the next level with our full suite of features, known and used by millions throughout the trading world.Learn more